Fitusiran: First Approval
Author:
Top Cited Papers
- 28 June 2025
- journal article
- other
- Published by Springer Nature in Drugs
- Vol. 85 (8) , 1073-1077
Abstract
Haemophilia A and B are inherited bleeding disorders caused by mutations in clotting factors. Small interfering RNA therapies may be utilised to restore coagulation by preventing the synthesis of antithrombin. Fitusiran (QFITLIA™) is a small interfering RNA therapy that targets antithrombin, which is being developed by Sanofi for the prophylactic management of haemophilia A and B with or without inhibitors. Fitusiran has the potential to be administered less frequently than other prophylactic treatments for haemophilia. This article summarizes the milestones in the development of fitusiran leading to this first approval for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and paediatric patients aged 12 years and older with haemophilia A or B with or without factor VIII or IX inhibitors.Keywords
This publication has 8 references indexed in Scilit:
- Clinical and molecular features of immunodeficiency in patients with telomere biology disordersBlood, 2025
- Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE studyBlood, 2025
- Fitusiran reduces bleeding in factor X–deficient miceBlood, 2024
- Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trialBlood, 2024
- Antithrombin-lowering in hemophilia: a closer look at fitusiranResearch and Practice in Thrombosis and Haemostasis, 2023
- RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient SelectionJournal of Blood Medicine, 2023
- Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trialThe Lancet, 2023
- Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trialThe Lancet Haematology, 2023